Do US Adults Use More Prescription Drugs Than Canadians?
Prescription drug use appears to be similar in the US and Canada, according to a new data brief from the Centers for Disease Control and Prevention (CDC).
Hyperlipoproteinemias
Evinacumab Effective in Homozygous Familial Hypercholesterolemia Trial
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Discontinuing Statins Linked to Cardiac Admissions in Elderly
Admission risk for any cardiovascular event up with discontinuation among previously adherent seniors.
FDA Recalls Herbal Meds Being Marketed for Various Diseases
In addition to being manufactured outside of the controls required by current Good Manufacturing Practices, these products are also being marketed for diseases without FDA approval.
Higher Intensity Therapy With Simvastatin-Ezetimibe May Benefit Elderly Patients After ACS
According to the results of a secondary analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), treatment with simvastatin-ezetimibe appears to be beneficial for patients ≥75 years old with stabilized acute coronary syndrome (ACS), compared with simvastatin alone. IMPROVE-IT was a randomized, double-blind, multicenter study that evaluated the outcomes and risks…
RNAi Therapy for Homozygous Familial Hypercholesterolemia Gets Orphan Drug Designation
The Food and Drug Administration (FDA) has granted Orphan Drug designation to ARO-ANG3 (Arrowhead Pharmaceuticals) for the treatment of homozygous familial hypercholesterolemia. ARO-ANG3 is a subcutaneously administered ribonucleic acid interference (RNAi) investigative treatment that works by reducing production of angiopoietin-like protein 3 (ANGPTL3), an inhibitor of lipoprotein lipase and endothelial lipase in the liver. The…
FDA Approves Sprinkle Formulation of Rosuvastatin
The Food and Drug Administration (FDA) has approved a new sprinkle formulation of rosuvastatin, an HMG Co-A reductase inhibitor. Ezallor Sprinkle (Sun Pharma) is indicated for the treatment of adult patients with: hypertriglyceridemia as an adjunct to diet; primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet; and homozygous familial hypercholesterolemia to reduce LDL-C,…
Lipid-Lowering Effects of Turmeric, Curcuminoids Examined
Findings of a recently published systematic review and meta-analysis revealed that turmeric and curcuminoids can significantly alter blood lipid levels in patients with metabolic diseases.
RNAi Therapeutic Gets Orphan Drug Status for Familial Chylomicronemia Syndrome
The Food and Drug Administration (FDA) has granted Orphan Drug designation to ARO-APOC3 (Arrowhead Pharmaceuticals), an investigational treatment for familial chylomicronemia syndrome (FCS). In FCS, mutations in lipoprotein lipase lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia. ARO-APOC3 is a subcutaneously administered RNAi therapeutic that targets apolipoprotein C-III (apoC-III), which according…
Does the Use of DPP4-is in Combination With Statins Increase Myopathy Risk?
FAERS database collects adverse events submitted by pharmaceutical companies, clinicians, and patients.
